Anvisa Tightens Control on Weight Loss Drugs like Ozempic, Wegovy & Mounjaro – what You Need too Know
RIO DE JANEIRO, BRAZIL – As of today, Monday, June 23rd, a new regulation from Brazil’s National Health Surveillance Agency (Anvisa) is taking effect, placing medications like Ozempic, Wegovy, and Mounjaro under stricter control. The move aims to combat self-medication and the indiscriminate use of these increasingly popular drugs [Anvisa].
What’s Changing?
Previously available with a standard prescription, these medications – which include semaglutide, liraglutide, dulaglutide, tirzepatide, and lixisenatide – will now require a “controlled revenue” prescription, similar to the requirements for antibiotics [ANVISA’s measure]. This means patients will need updated prescriptions for continued access.
Why the Change?
The decision follows a request from medical entities concerned about the widespread, and often inappropriate, use of these drugs. Anvisa director Daniel pereira stated the regulation aligns with the agency’s mission to protect public health
